Almirall Deal History & Licensing Activity
Almirall is a mid-size pharma headquartered in Belgium. Over the past three years, Almirall has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 17 active clinical trials, primarily in Autoimmune.
Deals (12mo)
2
Active Trials
17
Top Modality
Other
Focus Area
Autoimmune
Almirall Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Almirall in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| global licensing | Shanghai Huaota Biopharmaceutical | Other | Unknown | license | Mar 2026 |
Almirall Pipeline Focus
Therapeutic areas and modalities where Almirall is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Almirall Strategic Signals
Key indicators of Almirall's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Almirall Clinical Pipeline
Almirall has 17 active clinical trials across 6 development phases.
6
Unknown
2
Phase 4
1
Not Applicable
2
Phase 1
2
Phase 2
4
Phase 3
See How Your Asset Matches Almirall's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Almirall Licensing & Deal Activity
Almirall is a mid-size pharma company based in Belgium that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Almirall ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Almirall include Autoimmune (13 deals and trials), Mega Deals (2 deals and trials), Immunology (1 deal and trial), and Hematological Malignancies (1 deal and trial). In terms of modality, Almirall has shown particular interest in other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Almirall and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Almirall's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.